The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Clinical Study on the Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.

Study Overview

• Status: Recruiting
• Conditions: Advanced Pancreatic Cancer
• Intervention / Treatment: Drug: Adoptive TIL-TCM transfer therapy

Detailed Description

This is a single arm, open-label, single-center study.This study is indicated for advanced relapse-refractory or metastatic pancreatic cancer.The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. Primary objective is to explore the safety, main consideration is dose-related safety.

• Study Type: Interventional
• Enrollment (Anticipated): 3
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Xinbo Wang, MD; Phone Number: 13505172912; Email: wxinbo2008@163.com
• Study Contact Backup: Name: Sizhen Wang, MD; Phone Number: 15195900565; Email: wsizhen@163.com

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Recruiting
      • Jinling Hospital
      • Contact: Xinbo Wang, MD; Phone Number: 13505172912; Email: wxinbo2008@163.com
      • Contact: Sizhen Wang, MD; Phone Number: 15195900565; Email: wsizhen@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Aged≥18 years old and ≤70 years old when signing the informed consent; regardless of gender;Body weight>40kg.
2. Patients with advanced recurrent refractory or metastatic pancreatic cancer who have failed at least one standard treatment or who are unable to tolerate, unwilling or financially unable to receive standard treatment.
3. The subject will have at least one eligible tissue or sample available for cell preparation.
4. Patients with brain metastatic lesions who are asymptomatic , the diameter of a single lesion ≤1 cm, and the number of lesions ≤3 may be eligible.
5. Patients should have good clinical presentation status (ECOG 0 or 1).
6. HIV antibody and treponema pallidum antibody was negative.
7. Vital organ function test (do not accept any cytokines or blood transfusion within 14 days prior to test):

1)absolute neutrophil count (ANC) ≥1000/μL; 2)White blood cell count (WBC) 3000/μL; 3)Platelet count (PLT) 75,000 /μL; 4)Hemoglobin (Hb) > 8.0 g/dL; 5) Coagulation: activated partial thromboplastin time (APTT) ≤1.5×ULN, international normalized ratio (INR) or Prothrombin time (PT)≤1.5×ULN; 6) Liver functions: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤5.0 ×ULN; 7) Liver functions:Total bilirubin (TBIL)<1.5×ULN (baseline value normal); <1.0 - 1.5×ULN( baseline value abnormal); If diagnosed as Gilbert syndrome, ≤3.0 mg/dL; The test results should prevail of the center laboratory ; 8)Renal function: eGFR>60 mL/min or 6-24 hours CrCl>60 mL/min; 9)Heart Doppler ultrasound:LVEF≥50%;

8.Non-surgically sterilized women of child-bearing age are required to consent to use at least one medically approved contraceptive method during the study and one year after completion.Women of child-bearing age must be negative for pregnancy test at 7 days before initiation of the treatment.Male subjects must agree to use medically approved contraception from the time they sign the informed consent form to the time they leave the study.

9.Expected survival no less than 3 months.

Exclusion Criteria:

1. Pregnancy or lactation;
2. Active infections requiring systemic anti-infective therapy ( topical antibiotics excepted);
3. Patients who are taking systemic steroids or immunosuppressive drugs;
4. Hepatitis B (hepatitis B surface antigen [HbsAg] and/or core antibody [HbcAb] positive, HBV-DNA<1000 copies /mL can be included);
5. Hepatitis C ( HCV antibody positive and HCV-RNA positive);
6. Serious autoimmune diseases or immunodeficiency disease, such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (eg., Wegener's granulomatosis);
7. Allergic:Severe allergies to the drugs used in the study; Contraindications for IL-2 used ;
8. Patients with other active malignancies within the past 5 years, but not those who were clinically cured within 5 years of diagnosis of cervical epithelial carcinoma, basal or squamous skin cancer, superficial bladder cancer, breast cancer in situ and did not require follow-up;
9. Any mental diseases, including dementia and changes in mental status that may influence the understanding about the informed consent and questionnaire;
10. Unstable disease of heart head blood-vessel, including but not limited to, the heart cerebrovascular accident or transient ischemic (within 6 months prior to screening) myocardial infarction (within 6 months prior to screening)/vein thrombosis (within 6 months prior to screening, require surgery to repair the aortic aneurysm or proximal artery thrombosis group shall not enter into) unstable angina New York Heart Association (NYHA) Classification≥ III congestive heart failure severe arrhythmias poorly controlled by medications and severe hypertension that cannot be controlled by treatment or is untreated (systolic pressure≥160 mmHg and/or diastolic pressure≥100 mmHg );
11. Patients with severe interstitial pneumonia other active pneumonia or bronchospasm and other respiratory diseases that seriously affect lung function;
12. Patients with active gastrointestinal bleeding;
13. Had major surgery within 1 month prior to screening or during the study ;
14. Enrolled in other clinical trials (including other adoptive cell immunotherapies) and used the investigational drug within 1 month prior to screening.
15. Have received live attenuated vaccine within 1 month prior to screening or are expected to receive live attenuated vaccine during the study ;
16. Received any systemic antitumor drug therapy (including chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy or other biotherapy) within 4 weeks prior to pretreatment;
17. Have previously received allogeneic bone marrow transplantation or solid organ transplantation;
18. Alcohol, drug or substance abuse;
19. Judged as serious uncontrollable diseases by the researchers, or other conditions that may interfere with the treatment and therefore being ineligible.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: adoptive TIL-TCM transfer; TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators.TIL-TCM cells are transfused to patients in a dosage escalated manner.The total dose was 1× 109-1 ×1010 cells.After cell infusion, IL-2 was administered at 720000 IU/kg (based on whole body weight) by intravenous (I.V.),every 8 hours for up to 4 days.

Drug: Adoptive TIL-TCM transfer therapy; Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy; Other Names: TIL-TCM

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose-limiting toxicity (DLT)	To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer	Baseline up to 28 days after TIL-TCM cells infusion
Maximum Tolerated Dose（MTD）	To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer	Baseline up to 28 days after TIL-TCM cells infusion
incidence of adverse events( AE )and Serious adverse events(SAE)	Adverse events assessed according to NCI-CTCAE v5.0 criteria.	up to 72 weeks after TIL-TCM cells infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR)	ORR is defined as the percentage of patients who have a clinical response (objective tumor regression).ORR is computed by: the sum of the number of patients with Complete Response (CR) and number of patients with Partial Response (PR) / total number of patients. The total number of patients is the sum of the number of patients with CR, PR, stable disease (SD) or progressive disease (PD). The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) is used as the criteria to determine whether a tumor disappears (CR), shrinks (PR), stays the same (SD) or gets bigger (PD).	18 months
Duration of response (DOR)	DOR is the time between the initial response to treatment per RECIST v1.1 and subsequent disease progression among patients achieving Complete Response (CR) or Partial Response (PR). RECIST v1.1 is used as the criteria to determine whether a tumor disappears (CR) or shrinks (PR).	18 months
Progression-free survival (PFS)	PFS is the length of time from the date patient enrolled in to the date on which tumor progresses or the patient dies for any cause.	18 months

Collaborators and Investigators

• Sponsor: Sizhen Wang
• Collaborators: Shanghai Biomed-union Biotechnology Co., Ltd.
• Investigators: Study Director: Xinbo Wang, MD, Jinling Hospital,Nanjing University

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 2, 2021
• Primary Completion (ANTICIPATED): April 1, 2024
• Study Completion (ANTICIPATED): April 1, 2024

Study Registration Dates

• First Submitted: June 26, 2022
• First Submitted That Met QC Criteria: June 29, 2022
• First Posted (ACTUAL): June 30, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 30, 2022
• Last Update Submitted That Met QC Criteria: June 29, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: 2022DZKY-039-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No